Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Medtronic
McKesson
Express Scripts
McKinsey

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PHENTERMINE RESIN 30

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Phentermine Resin 30

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000506 ↗ Cardiovascular System in Obesity: Effect of Treatment Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1983-05-01 To determine the long-term efficacy of the combination therapy of phentermine and fenfluramine in conjunction with diet, exercise, and behavior modification in the treatment of simple, moderate obesity.
NCT00402077 ↗ A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects Completed AstraZeneca Phase 2 2006-11-01 This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
NCT00518466 ↗ Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults Completed VIVUS, Inc. Phase 1 2007-07-01 The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.
NCT00563368 ↗ A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults Completed Medpace, Inc. Phase 3 2007-12-01 The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
NCT00563368 ↗ A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults Completed VIVUS, Inc. Phase 3 2007-12-01 The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Phentermine Resin 30

Condition Name

Condition Name for Phentermine Resin 30
Intervention Trials
Obesity 27
Overweight 3
Drug Abuse 3
Bariatric Surgery 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Phentermine Resin 30
Intervention Trials
Obesity 19
Overweight 9
Weight Loss 5
Obesity, Morbid 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Phentermine Resin 30

Trials by Country

Trials by Country for Phentermine Resin 30
Location Trials
United States 79
Mexico 2
Korea, Republic of 1
Canada 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Phentermine Resin 30
Location Trials
California 11
Florida 6
Minnesota 6
Texas 5
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Phentermine Resin 30

Clinical Trial Phase

Clinical Trial Phase for Phentermine Resin 30
Clinical Trial Phase Trials
Phase 4 11
Phase 3 5
Phase 2 14
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Phentermine Resin 30
Clinical Trial Phase Trials
Completed 25
Recruiting 10
Withdrawn 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Phentermine Resin 30

Sponsor Name

Sponsor Name for Phentermine Resin 30
Sponsor Trials
VIVUS, Inc. 7
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 6
AstraZeneca 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Phentermine Resin 30
Sponsor Trials
Other 40
Industry 23
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Merck
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.